Core Insights - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [2][3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated LDL-C levels [2] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [2] Company Developments - Esperion will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 3:30 p.m. ET [1] - The company continues to evolve through commercial execution, international partnerships, and advancements in its pre-clinical pipeline [3] Contact Information - Investor relations contact: Alina Venezia, email: investorrelations@esperion.com, phone: (734) 887-3903 [4] - Media contact: Tiffany Aldrich, email: corporateteam@esperion.com, phone: (616) 443-8438 [4]

Core Insights - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [2] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated LDL-C levels [2] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [2] Company Developments - Esperion will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 8:00 a.m. GMT [1] - The company continues to evolve through commercial execution, international partnerships, and advancements in its pre-clinical pipeline [3] Contact Information - Investor relations contact: Alina Venezia, email: investorrelations@esperion.com, phone: (734) 887-3903 [4] - Media contact: Tiffany Aldrich, email: corporateteam@esperion.com, phone: (616) 443-8438 [4]

Core Insights - Esperion will report its third quarter 2025 financial results on November 6, 2025, before market opens, followed by a management webcast at 8:00 a.m. ET to discuss the results and provide business updates [1][2] Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease with elevated LDL-C levels, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design to create potent and specific inhibitors [3][4] Business Development - Esperion is evolving into a leading global biopharmaceutical company through effective commercial execution, international partnerships, collaborations, and the advancement of its pre-clinical pipeline [4]

Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated low-density lipoprotein cholesterol (LDL-C) [3] - Esperion's medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients [3] Upcoming Financial Results - Esperion will report its second quarter 2025 financial results before the market opens on August 5, 2025 [1] - Following the financial results release, management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates [1] Business Development - The company is advancing its next-generation program focused on developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights into drug design [3] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international partnerships, and collaborations [4]

Core Insights - Esperion is participating in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET [1] - The company is focused on developing and commercializing FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease [2] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi) to create highly potent and specific inhibitors [2][3] Company Overview - Esperion Therapeutics is a commercial-stage biopharmaceutical company addressing unmet medical needs in cardiovascular health [2] - The company has conducted the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients to support its medications [2] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution and international partnerships [3]